Infectious Disease
1752 CE, Germany — De Bergen's clinical description
Rubella was a disease that attracted relatively little medical attention for most of its history, long regarded as a minor and self-limiting condition of childhood far less dangerous than measles or scarlet fever. German physicians were among the first to distinguish it as a separate clinical entity in the eighteenth century, which led to the informal name "German measles" persisting in English-language usage for generations. The condition's historical significance was dramatically reframed in the twentieth century when researchers established its devastating consequences during pregnancy, a discovery that fundamentally changed both public health policy and the science of vaccines.
Historical Narrative
Early medical literature rarely distinguished rubella from other febrile rash-producing illnesses that circulated commonly among children in Europe and elsewhere. Ancient and medieval physicians who wrote about epidemic diseases involving fever and skin eruptions were unlikely to have separated rubella from measles, scarlet fever, or roseola, as the clinical tools to differentiate such conditions did not exist. The concept of rubella as a distinct disease entity was effectively absent from the written medical record until the eighteenth century.
The first systematic attempt to characterize rubella as a condition separate from measles and scarlet fever came from German physicians in the mid-eighteenth century. De Bergen in 1752 and Orlow in 1758 described an illness they considered distinct, and their work contributed to the disease acquiring the colloquial designation "Rötheln" in German medical literature. The name referenced the characteristic rash. Scottish physician William George Maton presented what was considered an early English-language clinical description in 1815, carefully arguing that the condition deserved recognition as a distinct disease rather than merely a mild variant of measles or scarlet fever.
The International Congress of Medicine in London in 1881 officially recognized rubella as a separate clinical entity, a formal step that reflected growing consensus among European physicians. Despite this recognition, the condition continued to be regarded as a relatively benign childhood illness warranting little alarm or intensive medical study. It did not carry the severity or mortality associated with smallpox, diphtheria, or even measles, and consequently attracted proportionally less scientific attention.
The Australian ophthalmologist Norman McAlister Gregg made the pivotal discovery in 1941 that transformed how medicine understood rubella. Gregg noticed an unusual cluster of infants with congenital cataracts in his practice and, through careful case history investigation, identified that their mothers had contracted rubella during early pregnancy. He published his findings in the Transactions of the Ophthalmological Society of Australia, reporting that maternal rubella infection was associated not only with cataracts but also with heart defects and low birth weight in newborns. Gregg's work was initially met with some skepticism but was rapidly confirmed by researchers in other countries.
This discovery recast rubella from a medical footnote into a major public health concern. Subsequent research through the 1940s and 1950s extended the catalog of developmental consequences associated with maternal infection, and the concept of what became known as congenital rubella syndrome gained scientific and clinical recognition. A major global epidemic of rubella in 1962 and 1963 affected hundreds of thousands of people across the United States and internationally, resulting in a wave of infants born with serious disabilities and driving urgent calls for the development of a preventive vaccine.
Virologists Thomas Huckle Weller and Franklin Allen Neva successfully isolated the rubella virus in 1962, a crucial technical achievement that made vaccine development possible. Harry Martin Meyer Jr. and Paul Douglas Parkman also independently isolated the virus that same year. These isolation efforts paved the way for vaccine development programs in the 1960s, with several research groups competing to produce a viable immunizing agent. Stanley Plotkin at the Wistar Institute and other researchers developed vaccine strains that moved through clinical testing during the late 1960s, culminating in licensed vaccines becoming available by 1969. The story of rubella thus moved across two centuries from an unremarkable childhood rash to a catalyst for landmark discoveries in teratology, virology, and vaccinology.
Key Historical Figures
Historical narrative only — this page describes how Rubella was understood historically. It is not medical advice and does not describe current diagnosis or treatment. Sourced from verified medical history references (NIH, Encyclopaedia Britannica, and standard medical history texts). See our medical disclaimer.